450.8500 3.70 (0.83%)
NSE Dec 30, 2025 15:31 PM
Volume: 151.6K
 

450.85
0.83%
ICICI Securities Limited
We recently hosted Akums’ management for a roadshow. Akums has been able to maintain its CDMO and overall EBITDA margin at 15.5%/12.0% despite its sub-par revenue growth in 9MFY25. Further efforts towards curbing losses in API division and new export order (starting CY27) could drive operating leverage and boost margins in coming years.
Akums Drugs & Pharma has lost -32.55% in the last 1 Year
More from Akums Drugs & Pharmaceuticals Ltd.
Recommended